8640 Stock Overview
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$3.52 |
| 52 Week Low | US$1.58 |
| Beta | -0.17 |
| 11 Month Change | -11.68% |
| 3 Month Change | 18.87% |
| 1 Year Change | -25.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8640 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | 1.1% |
| 1Y | -25.0% | -18.8% | 7.2% |
Return vs Industry: 8640 underperformed the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: 8640 underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 8640 volatility | |
|---|---|
| 8640 Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8640's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8640's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Bas van der Baan | lixte.com |
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| 8640 fundamental statistics | |
|---|---|
| Market cap | €4.62m |
| Earnings (TTM) | -€3.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 8640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8640 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.00m |
| Earnings | -US$4.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8640 perform over the long term?
See historical performance and comparison